Emcure Pharma Reduces Poviztra® Starting Dose Price by 55% to Expand Patient Access

• Poviztra® (0.25 mg) will now be available at Rs. 999/- per week or Rs. 3,999/- per month inclusive of taxes
• Prices of Poviztra® reduced by 47% on average across doses

Bangalore: Emcure Pharmaceuticals Ltd., (BSE: 544210, NSE: EMCURE) has announced the price revision of its weight management drug Poviztra® (semaglutide injection) across India. The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk’s semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

The price revision, effective April 3, 2026, will bring the innovator molecule, backed by robust clinical and real-world evidence, within the reach of a significantly larger patient base across the country – at a time when obesity and weight-related health conditions are emerging as one of India’s most pressing public health challenges.

The innovator biologic rDNA semaglutide molecule has been on the market for close to a decade. It is the most studied and used semaglutide globally with an equivalent of 49+ million patient years of exposure.1 It is backed by nearly 50 clinical trials in diverse clinical settings1 and has been taken by millions of patients worldwide2.

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity.3 Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”

Obesity is linked to over 230 health complications including cardiovascular disease, type 2 diabetes , hypertension, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alzheimer’s disease.4 With this price reduction, Emcure Pharma reinforces its commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of obesity in India.